1. ®cGMP, cGTP Facility Design for Production of Human Cells, Tissues and Tissuebased products Presented by Kris Chatrathi atInternational Society for Pharmaceutical Engineering-Midwest…

CAPA, Root Cause Analysis, and Risk Management By Joseph F. Tarsio, M.B.A., Ph.D. March 17, 2015 What is CAPA? Corrective and Preventative Action (CAPA) is a system of quality…

Slide 1 FDA Oversight of Cell Therapy Clinical Trials Celia Witten, Ph.D., M.D. Office Director, Office of Cellular, Tissue, and Gene Therapies CBER/FDA ISSCR/CIRM/ISCT Workshop…

Slide 1 organized in 1999 under the Subcommittee on Biotechnology of the National Science and Technology Council (NSTC) means by which Federal agencies involved in tissue…

The Market For Human Tissue Katherine M. Sauer University of Southern Indiana [email protected] April 3rd , 2008 MBAA â ABE Annual Conference Chicago, IL In the news⦅

Overview General Principles Legal & Regulatory Framework Impact Alternative Approaches Issues/Concerns Take Home Combination Products Combinations of different types…

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014 Outline Good Guidance Practices Guidance basics Guidances…

CAPA, Root Cause Analysis, and Risk Management By Joseph F. Tarsio, M.B.A., Ph.D. March 17, 2015 What is CAPA? Corrective and Preventative Action (CAPA) is a system of quality…

[Code of Federal Regulations] [Title 21, Volume 4] [Revised as of April 1, 2014] [CITE: 21CFR211] TITLE 21--FOOD AND DRUGS CHAPTER I--FOOD AND DRUG ADMINISTRATION DEPARTMENT…

Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies; CBER TSEAC 12-13 February…